Triple
T5689115
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Study 301 |
E125384
|
entity |
| Predicate | sponsorDrugGeneric |
P65956
|
FINISHED |
| Object | lecanemab |
E25439
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: lecanemab | Statement: [Study 301, sponsorDrugGeneric, lecanemab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: lecanemab Context triple: [Study 301, sponsorDrugGeneric, lecanemab]
-
A.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Leqembi
chosen
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
D.
Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
-
E.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: sponsorDrugGeneric Context triple: [Study 301, sponsorDrugGeneric, lecanemab]
-
A.
approvedDrugForm
Indicates that a particular pharmaceutical form (e.g., tablet, injection) is an officially approved formulation of a given drug.
-
B.
protectedDrugClassesInclude
Indicates that the specified set of protected drug classes includes the referenced drug class or classes.
-
C.
isProdrugOf
Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
-
D.
usesDrug
Indicates that an entity consumes, administers, or otherwise makes use of a specified drug.
-
E.
FDAApprovalType
Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0082bb19c8190823a4facd3cba79b |
completed | March 22, 2026, 3:18 p.m. |
| NER | Named-entity recognition | batch_69c029014588819094a2a0f6f9b66bab |
completed | March 22, 2026, 5:38 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c0a15254788190bd5d533df9c1fa26 |
completed | March 23, 2026, 2:11 a.m. |
| PD | Predicate disambiguation | batch_69c021c0e0408190ab6c3cd3f907e80f |
completed | March 22, 2026, 5:07 p.m. |
| PDg | Predicate description generation | batch_69c028fec2bc819083f5dca6a8d9d435 |
completed | March 22, 2026, 5:38 p.m. |
Created at: March 22, 2026, 3:44 p.m.